Share This Article:

Development and in Vitro-in Vivo Evaluation of Controlled Release Matrix Tablets of Desvenlafaxine

Abstract Full-Text HTML Download Download as PDF (Size:268KB) PP. 15-19
DOI: 10.4236/pp.2012.31003    6,565 Downloads   15,495 Views   Citations

ABSTRACT

The objective of this investigation was to prepare extended release tablet containing matrix granules of Desvenlafaxine succinate monohydrate and to study its in vitro release and in vivo absorption. The design of dosage form was performed by choosing hydrophilic hydroxypropyl methyl cellulose (HPMC K100M), sodium carboxyl methyl cellulose (Blanose), microcrystalline cellulose (MCC) and lactose monohydrate polymers as matrix builders and polyvinyl pyrolidine (Kollidon K30) as granulating polymers. Granules were prepared by composing drug with HPMC K100M, sodium CMC, MCC and lactose monohydrate by spray drying method. Optimized formulation of Desvenlafaxine succinate monohydrate was formed by using 20% HPMC K100M, 26.6% MCC, 6.6% of sodium CMC (Blanose), 13.3% of lactose monohydrate and 5% ratio of Kollidon K30 as binder. Tablets were compressed with free flowing optimized granules of uniform drug content. This extended the release period up to 24 h in vitro study. Similarity factor and mean dissolution time were also reported to compare various dissolution profiles. The network formed by HPMC, MCC and Blanose had been coupled satisfactorily with the controlled resistance. Biopharmaceutical study of this optimized dosage form in rabbit model showed 24 h prolonged drug release in vivo. A close correlation (R2 = 0.9833) was established between the in vitro release and the in vivo absorption of drug. The results suggested that wet granulation with spray dried technique, is a suitable method to formulate sustained release Desvenlafaxine succinate monohydrate and it can Perform therapeutically better than conventional immediate release dosage form.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Dodda and P. B, "Development and in Vitro-in Vivo Evaluation of Controlled Release Matrix Tablets of Desvenlafaxine," Pharmacology & Pharmacy, Vol. 3 No. 1, 2012, pp. 15-19. doi: 10.4236/pp.2012.31003.

References

[1] P. D. Alfinito, C. Huseltona, X. H. Chena, D. Deecher, “Pharmacokinetic and Pharmacodynamic Profiles of the Novel Serotonin and nor Epinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Ovariectomized Sprague-Dawley Rats,” Brain Research, Vol. 1098, 2006, pp. 71-78.
[2] D. Z. Lieberman, S. H. Massey, “Desvenla-faxine in Major Depressive Disorder: An Evidence-Based Review of Its Place in Therapy,” Core Evidence, Vol. 4, 2009, pp. 67-82.
[3] B. N. Singh, “Modified-Release Solid Formulations for Colonic Delivery,” Recent Patents on Drug Delivery & Formulation, Vol. 1, No. 1, 2007, pp. 53-63. doi:10.2174/187221107779814122
[4] R. Perry, “Des-venlafaxine: A New Seratonin-Norepinephrine reuptake Inhibitor for the Treatment of Adults with Major Depressive Disorder,” Clinical Therapeutics, Vol. 31, Part 1, 2009, pp. 1374-1404. doi:10.1016/j.clinthera.2009.07.012,
[5] G. V?lgyi, E. Baka, “Study of pH-Dependent Solubility of Organic Bases. Revisit of Henderson-Hasselbalch relationship,” Analytica Chimica Acta, Vol. 673, No. 1, 2010, pp. 40-46. doi:10.1016/j.aca.2010.05.022
[6] M. J. Zou, Y. Wang, “Wax-Matrix Tablet for Time-Dependent Colon-Specific Delivery System of Sophora Flavescens Aiton: Preparationand in Vivo Evaluation,” Drug Develop-ment and Industrial Pharmacy, Vol. 35, No. 2, 2009, pp. 224-233. doi:10.1080/03639040802258854
[7] M. S. Islam, “In Vitro Release Kinetics Study of Diltiazem Hy-drochloride from Wax and Kollidon SR Based Matrix Tablets,” Iranian Journal of Pharmaceutical Research, Vol. 7, No. 2, 2008, pp. 101-108.
[8] S. B. Tiwari, T. K. Murthy, R. M. Pai, P. R. Mehta, P. B. Chowdary, “Controlled Release Formulation of Tramadol Hydrochloride Using Hydrophilic and Hydrophobic Matrix System,” AAPS PharmSciTech, Vol. 4, No. 3, 2003, pp. 18-23. doi:10.1208/pt040331
[9] F. Taneri, I. Ozcan, and T. Guneri, “In Vitro and in Vivo Evaluation of Oral Tablet Formulations Prepared with Ketoconazole and Hy-droxypropyl-β-cyclodextrin,” Drug Delivery, Vol. 17, No. 3, 2010, pp. 152-157.
[10] T. Ishikawa, Y. Watanabe, “Effect of Hydroxypropylmethylcellulose (HPMC) on Therelease Pro?les and Bioavailability of a Poorly Water-Solubledrug from Tablets Prepared Using Macrogol and HPMC,” International Journal of Pharmaceutics, Vol. 202, No. 1, 2000, pp. 173-178. doi:10.1016/S0378-5173(00)00426-9

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.